Ubiquitination network in the type I IFN‐induced antiviral signaling pathway
暂无分享,去创建一个
[1] Wen Zhang,et al. E3 Ubiquitin Ligases: The Operators of the Ubiquitin Code That Regulates the RLR and cGAS-STING Pathways , 2022, International journal of molecular sciences.
[2] J. Patton,et al. Rotavirus NSP1 Subverts the Antiviral Oligoadenylate Synthetase-RNase L Pathway by Inducing RNase L Degradation , 2022, mBio.
[3] S. Lippman,et al. JAK: Not Just Another Kinase. , 2022, Molecular cancer therapeutics.
[4] Xiaolong Wang,et al. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR , 2022, Journal of Hematology & Oncology.
[5] Bin Wang,et al. Depression compromises antiviral innate immunity via the AVP-AHI1-Tyk2 axis , 2022, Cell Research.
[6] H. Lv,et al. E3 ubiquitin ligase MID1 ubiquitinates and degrades type‐I interferon receptor 2 , 2022, Immunology.
[7] Qian Wang,et al. Down-regulation of circPTTG1IP induces hepatocellular carcinoma development via miR-16-5p/RNF125/JAK1 axis. , 2022, Cancer letters.
[8] Chuanwu Zhu,et al. LATS1 is a central signal transmitter for achieving full type-I interferon activity , 2022, Science advances.
[9] Z. Liu,et al. The E3 ubiquitin ligase, FBXW5, promotes the migration and invasion of gastric cancer through the dysregulation of the Hippo pathway , 2022, Cell death discovery.
[10] Xiaoying Hu,et al. The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.
[11] Chuanwu Zhu,et al. High salt activates p97 to reduce host antiviral immunity by restricting Viperin induction , 2021, EMBO reports.
[12] Jieliang Chen,et al. Interferon and Hepatitis B: Current and Future Perspectives , 2021, Frontiers in Immunology.
[13] Jun Wang,et al. HSV-1-encoded ICP0 degrades the host deubiquitinase BRCC36 to antagonize interferon antiviral response. , 2021, Molecular immunology.
[14] E. Marsh,et al. The Antiviral Enzyme, Viperin, Activates Protein Ubiquitination by the E3 Ubiquitin Ligase, TRAF6 , 2021, bioRxiv.
[15] C. Lamaze,et al. Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads , 2021, Frontiers in Immunology.
[16] Shitao Li,et al. Role of Post-Translational Modifications of cGAS in Innate Immunity , 2020, International journal of molecular sciences.
[17] Liping Wang,et al. Roles of IFN-γ in tumor progression and regression: a review , 2020, Biomarker research.
[18] P. Ma,et al. RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense , 2020, Cell Death & Differentiation.
[19] E. Kudryashova,et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection , 2020, bioRxiv.
[20] Qinxue Hu,et al. Herpes Simplex Virus Type 2 Inhibits Type I IFN Signaling Mediated by the Novel E3 Ubiquitin Protein Ligase Activity of Viral Protein ICP22 , 2020, The Journal of Immunology.
[21] V. Saini,et al. Impact and prognosis of the expression of IFN-α among tuberculosis patients , 2020, PloS one.
[22] H. Oshiumi. Recent Advances and Contradictions in the Study of the Individual Roles of Ubiquitin Ligases That Regulate RIG-I-Like Receptor-Mediated Antiviral Innate Immune Responses , 2020, Frontiers in Immunology.
[23] Jun Wang,et al. Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling , 2020, Nature Communications.
[24] Guang-Hui Qian,et al. Small‐molecule inhibitors of ubiquitin‐specific protease 7 enhance type‐I interferon antiviral efficacy by destabilizing SOCS1 , 2020 .
[25] Depei Wu,et al. BRCC36 functions noncatalytically to promote antiviral response by maintaining STAT1 protein stability , 2020, European journal of immunology.
[26] Li Zhu,et al. USP12 translocation maintains interferon antiviral efficacy by inhibiting CBP acetyltransferase activity , 2020, PLoS pathogens.
[27] Wei Li,et al. Targeting UBE4A Revives Viperin Protein in Epithelium to Enhance Host Antiviral Defense. , 2019, Molecular cell.
[28] I. Dikic,et al. Cellular quality control by the ubiquitin-proteasome system and autophagy , 2019, Science.
[29] S. Hohaus,et al. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial , 2019, Clinical Cancer Research.
[30] Ji-Long Chen,et al. Functional Involvement of Interferon-Inducible Transmembrane Proteins in Antiviral Immunity , 2019, Front. Microbiol..
[31] Kailin Xu,et al. ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase β-TrCP , 2019, Nature Microbiology.
[32] David M. Smith,et al. A Practical Review of Proteasome Pharmacology , 2019, Pharmacological Reviews.
[33] C. Winkler,et al. IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections , 2019, Front. Microbiol..
[34] Lidong Wang,et al. RNF168 facilitates proliferation and invasion of esophageal carcinoma, possibly via stabilizing STAT1 , 2018, Journal of cellular and molecular medicine.
[35] J. Babon,et al. The molecular details of cytokine signaling via the JAK/STAT pathway , 2018, Protein science : a publication of the Protein Society.
[36] T. Taniguchi,et al. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. , 2018, Cold Spring Harbor perspectives in biology.
[37] M. Raza,et al. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases , 2018, Biomolecular concepts.
[38] M. Oliveira,et al. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..
[39] Xiaofeng Zheng,et al. Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome , 2018, PLoS pathogens.
[40] J. Arnold,et al. A naturally occurring antiviral ribonucleotide encoded by the human genome , 2018, Nature.
[41] S. Yao,et al. The molecular basis of JAK/STAT inhibition by SOCS1 , 2018, Nature Communications.
[42] A. Gatignol,et al. ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication. , 2018, Cytokine & growth factor reviews.
[43] H. Oshiumi,et al. Regulation of RIG-I Activation by K63-Linked Polyubiquitination , 2018, Front. Immunol..
[44] W. Hong,et al. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway. , 2017, Cancer research.
[45] Peng Zhao,et al. JOSD1 Negatively Regulates Type-I Interferon Antiviral Activity by Deubiquitinating and Stabilizing SOCS1. , 2017, Viral immunology.
[46] C. Scagnolari,et al. Role of Interferons in Chronic Hepatitis C Infection. , 2017, Current drug targets.
[47] C. Johansson,et al. Type I Interferons as Regulators of Lung Inflammation , 2017, Front. Immunol..
[48] Y. Crow,et al. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.
[49] Manoj N. Krishnan,et al. Global functional profiling of human ubiquitome identifies E3 ubiquitin ligase DCST1 as a novel negative regulator of Type-I interferon signaling , 2016, Scientific Reports.
[50] Guang-Hui Qian,et al. Ubiquitin-dependent Turnover of Adenosine Deaminase Acting on RNA 1 (ADAR1) Is Required for Efficient Antiviral Activity of Type I Interferon* , 2016, The Journal of Biological Chemistry.
[51] Jianfeng Dai,et al. Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus , 2016, PLoS pathogens.
[52] A. Brass,et al. The IFITMs Inhibit Zika Virus Replication. , 2016, Cell reports.
[53] M. Arnold,et al. Rotavirus NSP1 Associates with Components of the Cullin RING Ligase Family of E3 Ubiquitin Ligases , 2016, Journal of Virology.
[54] I. Dikic,et al. Ubiquitin chain diversity at a glance , 2016, Journal of Cell Science.
[55] Jun Chen,et al. Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway , 2016, Oncotarget.
[56] G. Conn,et al. Adenovirus VA RNA: An essential pro-viral non-coding RNA. , 2016, Virus research.
[57] H. Ezelle,et al. International Journal of Molecular Sciences the Roles of Rnase-l in Antimicrobial Immunity and the Cytoskeleton-associated Innate Response , 2022 .
[58] Nicholas M. Chesarino,et al. E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3 , 2015, PLoS pathogens.
[59] M. Mitkiewicz,et al. [Ubiquitin as a regulator of IFN production in the antiviral response]. , 2015, Postepy higieny i medycyny doswiadczalnej.
[60] S. Jonjić,et al. Varicella Viruses Inhibit Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms , 2015, PLoS pathogens.
[61] A. Oxenius,et al. Regulation of antiviral T cell responses by type I interferons , 2015, Nature Reviews Immunology.
[62] S. Bosinger,et al. Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy , 2015, Current HIV/AIDS Reports.
[63] A. Hauschild,et al. Who benefits most from adjuvant interferon treatment for melanoma? , 2015, American journal of therapeutics.
[64] B. Kelsall,et al. The role of type I interferons in intestinal infection, homeostasis, and inflammation , 2014, Immunological reviews.
[65] A. Brass,et al. IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores following Virus-Endosome Hemifusion , 2014, PLoS pathogens.
[66] M. Beard,et al. The role of viperin in the innate antiviral response. , 2014, Journal of molecular biology.
[67] Nicholas M. Chesarino,et al. Phosphorylation of the Antiviral Protein Interferon-inducible Transmembrane Protein 3 (IFITM3) Dually Regulates Its Endocytosis and Ubiquitination* , 2014, The Journal of Biological Chemistry.
[68] L. Ivashkiv,et al. Regulation of type I interferon responses , 2013, Nature Reviews Immunology.
[69] Ping Zhang,et al. Lack of RNase L Attenuates Macrophage Functions , 2013, PloS one.
[70] R. Greenberg,et al. A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. , 2013, Cell reports.
[71] Han Yang,et al. Ubiquitin-Specific Protease 13 Regulates IFN Signaling by Stabilizing STAT1 , 2013, The Journal of Immunology.
[72] B. Williams,et al. Fine tuning type I interferon responses. , 2013, Cytokine & growth factor reviews.
[73] Xiaolong Yang,et al. WWP1 E3 Ligase Targets LATS1 for Ubiquitin-Mediated Degradation in Breast Cancer Cells , 2013, PloS one.
[74] J. N. Clarke,et al. Viperin Is Induced following Dengue Virus Type-2 (DENV-2) Infection and Has Anti-viral Actions Requiring the C-terminal End of Viperin , 2013, PLoS neglected tropical diseases.
[75] U. Dittmer,et al. IFN‐α subtypes: distinct biological activities in anti‐viral therapy , 2013, British journal of pharmacology.
[76] D. Taatjes,et al. CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response , 2013, Immunity.
[77] D. Baker,et al. Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies , 2012, Proceedings of the National Academy of Sciences.
[78] Hideo Negishi,et al. The IRF family of transcription factors , 2012, Oncoimmunology.
[79] K. Malathi,et al. RNase L Induces Autophagy via c-Jun N-terminal Kinase and Double-stranded RNA-dependent Protein Kinase Signaling Pathways* , 2012, The Journal of Biological Chemistry.
[80] J. Kirkwood,et al. IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.
[81] N. Nasr,et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. , 2012, Blood.
[82] Ceshi Chen,et al. WWP1: a versatile ubiquitin E3 ligase in signaling and diseases , 2012, Cellular and Molecular Life Sciences.
[83] J. Darnell,et al. The JAK-STAT pathway at twenty. , 2012, Immunity.
[84] R. A. Karssemeijer,et al. S-Palmitoylation and Ubiquitination Differentially Regulate Interferon-induced Transmembrane Protein 3 (IFITM3)-mediated Resistance to Influenza Virus* , 2012, The Journal of Biological Chemistry.
[85] Jianni Qi,et al. Smurf1 Protein Negatively Regulates Interferon-γ Signaling through Promoting STAT1 Protein Ubiquitination and Degradation* , 2012, The Journal of Biological Chemistry.
[86] Thao Nguyen,et al. The interferons and their receptors—distribution and regulation , 2012, Immunology and cell biology.
[87] P. Cresswell,et al. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. , 2011, Cell host & microbe.
[88] S. Lemon,et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A , 2011, Hepatology.
[89] Gaurav D. Gaiha,et al. IFITM3 Inhibits Influenza A Virus Infection by Preventing Cytosolic Entry , 2011, PLoS pathogens.
[90] D. Baker,et al. Tyrosine Phosphorylation of Protein Kinase D2 Mediates Ligand-inducible Elimination of the Type 1 Interferon Receptor* , 2011, The Journal of Biological Chemistry.
[91] Anne Gatignol,et al. Enhancement of Replication of RNA Viruses by ADAR1 via RNA Editing and Inhibition of RNA-Activated Protein Kinase , 2011, Journal of Virology.
[92] C. Samuel,et al. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. , 2011, Virology.
[93] Y. She,et al. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability , 2011, Proceedings of the National Academy of Sciences.
[94] A. Kijlstra,et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease. , 2011, Rheumatology.
[95] D. Baker,et al. Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2 , 2010, Molecular and Cellular Biology.
[96] Xiaolong Yang,et al. LATS tumor suppressor: A new governor of cellular homeostasis , 2010, Cell cycle.
[97] E. Urcelay,et al. IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.
[98] C. Samuel,et al. RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment. , 2010, Virology.
[99] L. Moja,et al. Interferon-alpha for maintenance of follicular lymphoma. , 2010, The Cochrane database of systematic reviews.
[100] David J. Adams,et al. The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.
[101] D. Baker,et al. Inducible Priming Phosphorylation Promotes Ligand-independent Degradation of the IFNAR1 Chain of Type I Interferon Receptor* , 2009, The Journal of Biological Chemistry.
[102] C. Samuel,et al. Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha phosphorylation. , 2009, Journal of molecular biology.
[103] Roberto Cattaneo,et al. RNA-specific Adenosine Deaminase ADAR1 Suppresses Measles Virus-induced Apoptosis and Activation of Protein Kinase PKR* , 2009, The Journal of Biological Chemistry.
[104] David Komander,et al. Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.
[105] O. Crasta,et al. An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity , 2008, Proceedings of the National Academy of Sciences.
[106] E. Yang,et al. Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain , 2008, Proceedings of the National Academy of Sciences.
[107] D. Alberts,et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. , 2008, Gynecologic oncology.
[108] Dong-er Zhang,et al. ISG15 Inhibits Nedd4 Ubiquitin E3 Activity and Enhances the Innate Antiviral Response*♦ , 2008, Journal of Biological Chemistry.
[109] T. Taniguchi,et al. The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.
[110] D. Baker,et al. Ligand-independent pathway that controls stability of interferon alpha receptor. , 2008, Biochemical and biophysical research communications.
[111] B. Ramratnam,et al. Acetylation-Dependent Signal Transduction for Type I Interferon Receptor , 2007, Cell.
[112] A. Hovanessian. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2'-5'oligoadenylate synthetases and the protein kinase PKR. , 2007, Cytokine & growth factor reviews.
[113] Peter Cresswell,et al. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. , 2007, Cell host & microbe.
[114] R. Silverman,et al. Small self-RNA generated by RNase L amplifies antiviral innate immunity , 2007, Nature.
[115] Paul J. Hertzog,et al. Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.
[116] S. Pestka. The Interferons: 50 Years after Their Discovery, There Is Much More to Learn* , 2007, Journal of Biological Chemistry.
[117] P. Pitha,et al. The IRF family, revisited. , 2007, Biochimie.
[118] J. F. Burrows,et al. Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase , 2007, Journal of Virology.
[119] Ulrich Pfeffer,et al. Identification of Genes Selectively Regulated by IFNs in Endothelial Cells1 , 2007, The Journal of Immunology.
[120] Y. Nie,et al. Double-Stranded RNA Deaminase ADAR1 Increases Host Susceptibility to Virus Infection , 2006, Journal of Virology.
[121] C. Brosnan,et al. TLR3 Ligation Activates an Antiviral Response in Human Fetal Astrocytes: A Role for Viperin/cig51 , 2006, The Journal of Immunology.
[122] E. Coccia,et al. Toll-like Receptor-dependent and -independent Viperin Gene Expression and Counter-regulation by PRDI-binding Factor-1/BLIMP1* , 2006, Journal of Biological Chemistry.
[123] T. Robak. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. , 2006, Cancer treatment reviews.
[124] S. Fuchs,et al. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. , 2006, The Biochemical journal.
[125] L. Semendric,et al. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector , 2005, Hepatology.
[126] Takashi Tanaka,et al. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. , 2005, Immunity.
[127] C. D. Krause,et al. Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.
[128] S. Fuchs,et al. Phosphorylation and Specific Ubiquitin Acceptor Sites Are Required for Ubiquitination and Degradation of the IFNAR1 Subunit of Type I Interferon Receptor* , 2004, Journal of Biological Chemistry.
[129] Y. Kitade,et al. Structural basis for recognition of 2′,5′‐linked oligoadenylates by human ribonuclease L , 2004, The EMBO journal.
[130] G. Hall,et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study , 2004, British Journal of Cancer.
[131] Xiaolong Yang,et al. LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1 , 2004, Nature Cell Biology.
[132] T. Pawson,et al. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture , 2004, Oncogene.
[133] D. Hilton,et al. Inhibitors of Cytokine Signal Transduction* , 2004, Journal of Biological Chemistry.
[134] K. Pfeffer,et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. , 2003, Immunity.
[135] T. Decker,et al. Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons , 2003, EMBO reports.
[136] J. Turkson,et al. STAT3 Activation by Type I Interferons Is Dependent on Specific Tyrosines Located in the Cytoplasmic Domain of Interferon Receptor Chain 2c , 2002, The Journal of Biological Chemistry.
[137] G. Stark,et al. Interferon Signaling Is Dependent on Specific Tyrosines Located within the Intracellular Domain of IFNAR2c , 2002, The Journal of Biological Chemistry.
[138] T. Xu,et al. Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G2/M arrest or apoptosis , 2001, Oncogene.
[139] I. Kola,et al. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. , 2001, Blood.
[140] C. Horvath,et al. Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[141] P. Cohen,et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[142] M. S. St John,et al. The role of lats in cell cycle regulation and tumorigenesis. , 1999, Biochimica et biophysica acta.
[143] J. Hiscott,et al. The growing family of interferon regulatory factors. , 1997, Cytokine & growth factor reviews.
[144] J. Darnell. STATs and gene regulation. , 1997, Science.
[145] M J Clemens,et al. The double-stranded RNA-dependent protein kinase PKR: structure and function. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[146] Warren S. Alexander,et al. A family of cytokine-inducible inhibitors of signalling , 1997, Nature.
[147] S. Akira,et al. Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.
[148] Takaho A. Endo,et al. A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.
[149] G. Stark,et al. Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling , 1997, Molecular and cellular biology.
[150] J. Mattick,et al. Cloning and expression analysis of a novel mouse gene with sequence similarity to the Drosophila fat facets gene , 1997, Mechanisms of Development.
[151] Richard G Richards. Interferon beta in multiple sclerosis , 1996, BMJ.
[152] G. Stark,et al. Mutant U5A cells are complemented by an interferon‐alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. , 1995, The EMBO journal.
[153] B. Cohen,et al. Ligand-induced association of the type I interferon receptor components , 1995, Molecular and cellular biology.
[154] J. Darnell,et al. Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.
[155] C. Proud,et al. PKR: a new name and new roles. , 1995, Trends in biochemical sciences.
[156] T. Xu,et al. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. , 1995, Development.
[157] P J Bryant,et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. , 1995, Genes & development.
[158] O. Colamonici,et al. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase , 1994, Molecular and cellular biology.
[159] J. Johnston,et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[160] E. Génot. Interferon alpha and intracytoplasmic free calcium in hairy cell leukemia cells. , 1994, Leukemia & lymphoma.
[161] P. Lengyel. Tumor-suppressor genes: news about the interferon connection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[162] C. Samuel,et al. The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. , 1993, The Journal of biological chemistry.
[163] G. Gahrton,et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .
[164] S. Vedantham,et al. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. , 1992, Cancer research.
[165] C. Samuel,et al. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. , 1991, Virology.
[166] T. Shows,et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.
[167] J. Bazan. Shared architecture of hormone binding domains in type I and II interferon receptors , 1990, Cell.
[168] F. Mandelli,et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.
[169] R. Eddy,et al. Identification and chromosomal mapping of new human tyrosine kinase genes. , 1990, Oncogene.
[170] A. Wilks. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[171] W. Cendrowski. [Interferon in multiple sclerosis]. , 1981, Neurologia i neurochirurgia polska.
[172] J. Luban. SARS-CoV-2 , 2020 .
[173] W. Liu,et al. Nuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA , 2017, Nature Immunology.
[174] C. Andrewes,et al. Virus interference. I. The interferon , 2017 .
[175] A. Găman. Hairy cell leukemia--a rare type of leukemia. A retrospective study on 39 patients. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[176] J. D. Burke,et al. Antiviral strategies: the present and beyond. , 2009, Current molecular pharmacology.
[177] Stephen J. Elledge,et al. Supplemental Data The IFITM Proteins Mediate Cellular Resistance to Influenza A H 1 N 1 Virus , West Nile Virus , and Dengue Virus , 2009 .
[178] D. Alberts,et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. , 2006, Gynecologic oncology.
[179] N. Cordani,et al. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. , 2005, International journal of oncology.
[180] S. Fuchs,et al. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. , 2003, The EMBO journal.
[181] A. Lewis-Antes,et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.
[182] A. Eggermont. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma. , 2002, Expert review of anticancer therapy.
[183] A. Verma,et al. Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. , 2002, The Journal of biological chemistry.
[184] R. Silverman,et al. Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2',5'-oligoadenylate-dependent RNase L. , 2002, Viral immunology.
[185] John Kirkwood,et al. Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.
[186] C. Pickart,et al. Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.
[187] S. Krown. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[188] B. Williams,et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[189] J. Harris,et al. Recombinant human interferon-beta in the treatment of condylomata acuminata. , 1997, International journal of STD & AIDS.
[190] L. Platanias,et al. A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. , 1997, The Journal of biological chemistry.
[191] T. Maniatis,et al. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. , 1996, Science.
[192] B. Cohen,et al. The human interferon alpha/beta receptor: characterization and molecular cloning. , 1994, Cell.
[193] G. Gahrton,et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. , 1993, Blood.
[194] G. Lutfalla,et al. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. , 1990, Cell.
[195] H. Heimpel,et al. Deficient IFN alpha production in hairy cell leukemia. , 1986, Blut.
[196] Y. Kojima,et al. [Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus]. , 1958, Comptes rendus des seances de la Societe de biologie et de ses filiales.
[197] M. Jiang,et al. Nuclear RNF 2 inhibits interferon function by promoting K 33-linked STAT 1 disassociation from DNA , 2022 .